Literature DB >> 12380660

A new method to obtain and present complete information on the compatibility: study of its validity for eight binary mixtures of morphine with drugs frequently used in palliative care.

An Vermeire1, Jean Paul Remon, Dirk Schrijvers, Peter Demeulenaere.   

Abstract

Parenteral administration of mixtures of morphine with other drugs has become common practice in palliative care. Such mixtures are sometimes found to be incompatible but compatibility data are scarce. An attempt was made to develop a quick and simple investigation strategy to obtain complete information on the compatibility of two drugs. This strategy was then used to study the physical and chemical compatibility of morphine HCl with alizapride HCl, atropine sulphate, dexamethasone sodium phosphate, hyoscine butylbromide, metoclopramide HCl, octreotide lactate, ranitidine HCl and hyoscine hydrobromide. These compatibility data are presented in such a way that they are easy to use in clinical practice. The investigation strategy outlined here allows the collection of complete information on the compatibility of morphine with another drug by studying a limited number of carefully selected mixtures per combination. The mixtures to be studied are selected using a scheme in which all possible mixtures prepared by mixing morphine solutions of varying concentrations with a drug solution in different volume ratios can be visualized. Applying this strategy to the eight combinations revealed, except for ranitidine HCl, no physical (visual) or chemical (HPLC; >90%) incompatibility in any of the mixtures studied for seven days at 22 and 32 degrees C. This indicates that all possible mixtures of these drug solutions with morphine HCl are compatible. For the combination with ranitidine incompatibility was observed only when using morphine HCl solutions containing >40 mg/ml and at certain ratios (drug/morphine HCl [D/M]: 4/42, 10/6 and 8/8, v/v), but all physically compatible mixtures were chemically stable (>90%). Studying extra mixtures in addition to those required to be studied according to the strategy revealed no discrepancies for any of the eight combinations studied. Adaptation of the layout of the scheme and the design of a decision tree resulted in an easy tool to check compatibility in daily practice. The scheme designed in this study is a useful tool for research and for daily practice. It simplifies and thereby encourages investigation of the compatibility of drugs. The availability of data on the physical as well as chemical compatibility in daily practice will contribute to a better quality of the mixtures used in palliative care and help to avoid complications and inadequate symptom control.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12380660     DOI: 10.1191/0269216302pm542oa

Source DB:  PubMed          Journal:  Palliat Med        ISSN: 0269-2163            Impact factor:   4.762


  4 in total

1.  Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide.

Authors:  Emilia Barcia; Rodrigo Reyes; Maria Luz Azuara; Yolanda Sánchez; Sofía Negro
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

2.  Multidrug infusions in a Swiss palliative care unit: assessment of frequent combinations in terms of clinical effectiveness, compatibility, and stability.

Authors:  Tanja Fusi-Schmidhauser; Dario Caronzolo; Claudia Gamondi
Journal:  Support Care Cancer       Date:  2016-07-23       Impact factor: 3.603

3.  Stability of mixtures of ondansetron and haloperidol stored in infusors at different temperatures.

Authors:  María Espinosa-Bosch; Fuensanta Sanchez-Rojas; Catalina Bosch-Ojeda
Journal:  Eur J Hosp Pharm       Date:  2018-01-27

4.  Stability of octreotide acetate decreases in a sodium bisulfate concentration-dependent manner: compatibility study with morphine and metoclopramide injections.

Authors:  Kouichi Tanabe; Junko Wada; Jun Ohkubo; Atsumi Nitta; Tomoaki Ikezaki; Miyako Takeuchi; Aya Handa; Mai Tanaka; Nozomu Murakami; Tatsuhiko Kashii; Hidenori Kitazawa
Journal:  Eur J Hosp Pharm       Date:  2015-01-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.